– USA, MA – Regel Therapeutics, a next-generation gene therapy company utilizing proprietary technology to develop clinical products modulating gene expression, today announced the addition of Dr. Andrew Schiermeier (Ph.D.) to its Board of Directors.
“I have been fortunate to have been involved as a founder, early investor, and active board member of several transformative life sciences companies over the past several years including Cougar Biotechnology and Kite Pharma. Each of these companies started with unique and robust enabling technologies. But what made those enterprises profoundly successful was the relentless determination of our employees to make a material difference in people’s lives. As we strive to mature our pipeline and grow, that stands as our beacon at Regel as well.” said CEO, Steve Ruchefsky.
Andrew Schiermeier, former COO of Intellia and current CEO of Avencell Therapeutics joined the Regel Board.
Dr. Andrew Schiermeier said, “I have known Andrew for almost two decades. His understanding of science and technology, business instincts, and leadership are all equally strong making him somewhat of an outlier in the life sciences. I look forward to tapping into Andrew’s knowledge and experience to assist in developing Regel’s strategic initiatives and execution”.
“Regel is approaching gene therapy using some very differentiated and unique technologies. The pre-clinical data that they have already generated is quite impressive and promising for areas of genetic disease that have remained very challenging to date. I am excited to do whatever I can to assist the company in moving its multi-product platform forward into the clinical setting and to patients,” added Dr. Andrew Schiermeier.
About Regel Therapeutics.
Derived from breakthrough technologies developed by co-founders Jordane Dimidschstein Ph.D. and Navneet Matharu Ph.D. at the Broad Institute and UCSF, respectively, Regel’s T3 platform combines a deactivated Cas system, which precisely targets the epigenome without editing or damaging the DNA, and proprietary regulatory elements restricting the intervention exclusively to specific cell types. This approach allows for efficient and permanent restoration of normal gene expression exclusively to the cells affected by the disease. By providing three layers of specificity of intervention, this technology promises to significantly increase efficiency while reducing potential off-target or side effects. Regel’s approach is supported by years of discovery and innovation and is now poised to become the first-in-class therapeutic intervention to transform the lives of patients suffering from severe and life-threatening genetic diseases.
For more information: https://regeltherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
